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ABSTRACT 
Background: To analyze the academic characteristics, career trajectory, scholarly publications, and demographic background of 
the 100 most-cited authors in ophthalmic literature. 
Methods: In this observational cross-sectional study, a database containing every ophthalmology journal article from 1967 to 2018 
was built using Scopus journal article information. The 100 authors with the most citations were identified, along with a control 
group of authors with at least five publications. Information about each author, such as gender, institution, and educational 
degrees were found from online web searches. Intra- and inter-group analyses were performed to identify correlations that may 
lead to having a high level of impact in ophthalmology literature. 
Results: Of the 100 most-cited ophthalmologists, 56 practice in the United States (US) and only 12 are female. In an odds ratio 
(OR) analysis, highly-cited researchers more often lived in the US (OR, 2.97; P < 0.001), were male (OR, 2.4; P = 0.02), and graduated 
from an elite medical school (OR, 3.89; P = 0.02) and/or residency (OR, 3.67; P = 0.02), but were not from an undergraduate 
institution (P = 0.75). There was no difference in citation numbers between different ophthalmology subspecialties (P = 0.22) or 
advanced degrees (PhD, MPH in addition to MD). Women among the top-100-cited authors were more likely to author high impact 
journal articles (P < 0.05). 
Conclusions: Among highly-cited ophthalmologists, practicing in the US and attending a top medical school or residency program 
may provide training for a successful research career in ophthalmology. Additionally, top female ophthalmologists participate in 
more influential research. 
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INTRODUCTION 
The impact of a career in ophthalmic research is based on 
a series of decisions. These include selecting a medical 
school and residency program, choosing between 
academic and private practice, whether to pursue 
fellowship training and/or additional advanced degrees 
such as a Master of Public Health (MPH), Master of 
Business Administration (MBA), or Doctor of Philosophy 
(PhD). These options can be instrumental in facilitating a 
fruitful academic career [1-4]. Previous studies have 
described the characteristics of American ophthalmology 
residency program directors [1], department chairs [2], 
and clinician-scientists receiving National Institute of 
Health (NIH) grants [3]. Gershoni et al. investigated the 
impact of subspecialty choice on research productivity, 
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ABSTRACT
Backg ound: This study aimed to investigate retin l imaging biomarkers, such as disorganization of the retinal 
inner lay rs (DRIL) and/or llipsoid zone (EZ) disruption by spectral domain optical coherence tomography 
(SD-OCT), and functional outcomes in eyes treated with 0.2 µg/day of a fluocinolone acetonide intravitreal 
implant (FAc) after an insufficient response to previous treatments.
Methods: This was a retrospective comparative study of 18 eyes (15 patients) with persistent and/or recurrent 
diabetic macular edema (DME) treated with FAc. Eyes were divided according to the number of prior intravitreal 
treatments: group 1 (n = 8) with ≤ 6 injections (early switch) and group 2 (n = 10) with > 6 injections (late 
swi c ). Outcomes in lud d percentage f eyes with DRIL and/or EZ disruption at baseline and analysis of the 
best corrected visual acuity (BCVA) using ETDRS letters, central macular thickness (CMT), DRIL, and EZ 
disruption at the last observation.
Results: Group 2 revealed a significantly higher percentage of DRIL and/or EZ disruption than group 1 
(P < 0.05). At the last observation, group 1 revealed a higher percentage of eyes achieving vision stability/
improvement, gaining ≥15 letters, and achieving ≥70 letters (P > 0.05 for all comparisons). The mean BCVA 
g in wa  8.8 and 0.7 letters for groups 1 and 2 (P = 0.397). Both groups revealed a significant mean CMT 
reduction (>20% reduction from the baseline value), without a significant statistical difference between them 
(P = 0.749). After treat ent, most eyes from both gr ups showed resolution of DRIL and EZ disruption.
Conclusions: Patients with DME presenting with a lower percentage of DRIL and/or EZ disruption at baseline 
had better functional outcomes, supporting the possible benefit of an early switch to FAc after insufficient 
response to previous treatments. Future randomized studies with a larger patient cohort are warranted to 
confirm our conclusions.
KEY WORDS  
spectral domain optical coherence tomography, SD-OCT, diabetic macular edema, fluocinolone acetonide 
intravitreal implant, retina imaging biomarkers, disorganization of retinal inner layers, ellipsoid zone, 
prognostic biomarkers, central macular thickness
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properly cited. 
INTRODUCTION 
Diabetic macular edema (DME) is the most common cause of blindness in patients with diabetic retinopathy 
[1]. The prevalence of DME has been reported to be 24.5% in patients with type II diabetes throughout a 
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10-year period [2, 3]. Although hyperglycemia is considered a major risk factor for the development of DME, the 
exact mechanism of its pathogenesis remains unclear [4]. Hyperglycemia is responsible for the upregulation of 
inflammatory cytokines and growth factors such as interleukin (IL)-8, intercellular adhesion molecule 1 (ICAM-
1), and vascular endothelial growth factor (VEGF) [2, 4]. In its multifactorial nature, blood–retinal barrier 
dysfunction and inflammation may also play an important role [1, 4]. Therefore, besides anti-VEGF therapy, 
which is considered the mainstay of DME treatment [5, 6], intravitreal corticosteroids, acting mainly against the 
inflammatory component of DME, are becoming increasingly important, particularly in chronic or persistent 
DME [7-9]. Indeed, DME presents with a widely variable response to anti-VEGF treatment [1]. Protocols T 
and I in the Diabetic Retinopathy Clinical Research Network (DRCR.net) show that nearly 40% of eyes have 
persistent DME after six anti-VEGF monthly injections [10, 11].
The fluocinolone acetonide (FAc) implant is a non-biodegradable corticosteroid intravitreal implant that 
provides controlled and sustained drug release (0.2 µg/day) during 3 years [7, 12, 13]. It can act against pro-
inflammatory molecules such as VEGF-A, chemokines, and cytokines, reducing inflammation, angiogenesis, and 
vascular permeability [7, 13]. In Europe, the FAc implant is indicated for the treatment of chronic DME, which 
is considered insufficiently responsive to available therapies [3, 7]. Despite the higher risk of cataract formation 
and ocular hypertension associated with intravitreal corticosteroid agents [6], there are several benefits to using 
FAc implants. The benefits include fewer potential systemic side effects (from repeated anti-VEGF treatments), 
longer treatment intervals with reduction of treatment burden, and higher patient compliance [7, 8].
Spectral domain optical coherence tomography (SD-OCT), or athwart acquisition of high-resolution retinal 
anatomical images, offers a strong morpho–functional correlation that is particularly useful in DME management 
[1, 6]. 
Central retinal thickness (CMT) and other essential parameters, such as glycemic control, are considered 
insufficient and inadequate predictors of future visual acuity in patients with DME [14, 15]. The identification 
of reliable visual surrogates and functional prognostic markers to select appropriate intravitreal treatments 
and determine future therapeutic responses is now fundamental and urgent. Recently, SD-OCT has become 
extremely important in this field, allowing evaluation of retinal integrity through prognostic biomarker analysis, 
such as disorganization of the retinal inner layers (DRIL) and ellipsoid zone (EZ) disruption [6, 14-17].
Chronicity may play an important role in the development and evolution of DRIL [18], since patients with 
chronic DME have a higher incidence of this macular biomarker [17, 18]. For that reason, hypothetically, treating 
patients earlier may lead to better functional results, once retinal integrity at the baseline seems to be directly 
correlated with visual outcomes [17, 19]. However, as the pathogenesis of these biomarkers has been related to 
the inflammatory status of DME, treatment with FAc implants is particularly interesting in these eyes [17].
In eyes with chronic DME, we assessed the extent of DRIL and/or EZ disruption and compared these and 
functional outcomes following early or late switch to an FAc intravitreal implant.
METHODS
This non-interventional, retrospective, comparative, single-center study included 18 eyes from 15 patients with 
chronic DME (i.e., DME that persists or recurs despite treatment) [3]. The study was conducted at the Beatriz 
Ângelo Hospital, a tertiary referral center in Loures, Portugal. Patients were included if they had been treated 
with an FAc intravitreal implant according to the approved license in Europe and after providing informed 
consent. The study protocol was approved by the ethics committee of the institute (Health Ethical Committee 
of Beatriz Ângelo Hospital).
Two patient groups were devised based on the number of prior intravitreal treatments: group 1 included 8 
eyes (7 patients) that had received ≤ 6 prior intravitreal injections (early switch group; including anti-VEGF 
intravitreal injections such as bevacizumab [Avastin®; Roche®, Grenzach, Germany], aflibercept [Eylea®; 
Bayer Pharma AG®, Leverkusen, Germany], and ranibizumab [Lucentis®; Novartis®, Dublin, Ireland] or short-
acting corticosteroid intravitreal injections such as a triamcinolone (Intracinol®; Farmigea®, Pisa, Italy) or a 
dexamethasone (Ozurdex®; Allergan Inc®, Dublin, Ireland) and group 2 included 10 eyes (8 patients) that had 
received > 6 intravitreal injections (late switch group).
All patients underwent a complete ophthalmologic examination, which included best corrected visual acuity 
(BCVA), anterior and posterior segment slit-lamp evaluation (Takagi SM-70N, Takagi Seiko Co.,Ltd., Japan), 
and Goldmann applanation tonometry (AT 900R®, Haag-Streit, Koeniz, Switzerland). BCVA was measured 
using the Early Treatment Diabetic Retinopathy Study (ETDRS) protocol at a 4-meters distance with an ETDRS 
chart and calculated in accordance with the ETDRS scoring method [20]. 
In all patients, SD-OCT was performed at each visit using Spectralis (Heidelberg Engineering; Heidelberg, 
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Germany) in high resolution mode with 100 automatic real-time (ART) and 6 × 6 mm macular map. Vertical 
and horizontal linear scans centered on the fovea were obtained. Two independent blinded graders analyzed 
the following parameters: CMT, DRIL, and EZ disruption. DRIL and EZ were obtained on the 1-mm diameter 
central region, and the patient´s eyes were further classified according to the presence or absence of these 
imaging biomarkers. Foveal DRIL was defined as the inability to clearly distinguish the boundaries between the 
inner plexiform, inner nuclear, and outer plexiform layers [14, 15]. EZ disruption was defined as the inability to 
identify the continuity of the inner segment–outer segment photoreceptor junction and loss of reflectivity in 
these layers [14]. 
The inclusion criteria were diagnosis of diabetes mellitus type 2; the presence of clinically significant DME 
(according to ETDRS guidelines), either persistent or recurrent; and treatment with an intravitreal FAc implant 
for at least 12 months. The exclusion criteria were macular edema secondary to causes other than DME; the 
presence of concurrent retinal diseases such as macular degeneration or retinal vein occlusion; high media 
opacities; any ophthalmic surgery in the last 6 months prior to the FAc implant; and uncontrolled glaucoma or 
any history of uveitis or other ophthalmic or systemic disease potentially affecting the results of the study. 
Outcome measures included the percentage of eyes with DRIL and/or EZ disruption at baseline and analysis 
of the BCVA, CMT, and intraocular pressure (IOP) at baseline, months 1 and 3, and then quarterly thereafter 
until the last observation (mean ± standard deviation [SD], 2.43 ± 16.25 months for group 1 and 12.94 ± 15.00 
months for group 2). All outcomes were also analyzed at the last observation.
Descriptive statistics (means and absolute and relative frequencies) and inferential statistics were used. 
Statistical analysis was performed using IBM SPSS Statistics for Windows, version 25.0 (IBM Corp., Armonk, 
NY, USA). The paired sample Student’s t-test was performed to compare parametric data between groups, and 
the Wilcoxon non-parametric test was used for comparisons of non-parametric values. The Shapiro–Wilk test 
was used when the variables did not present a normal distribution. Fisher’s test was used when comparing groups 
in nominal type variables. The Yates Chi-square association test was also performed to compare the effect of 
treatment on OCT biomarkers between groups. The level of statistical significance was set at P < 0.05.
RESULTS
This study included 18 eyes (15 patients) with persistent and/or recurrent DME treated with FAc. Eyes were 
divided according to the number of prior intravitreal treatments: group 1 (n = 8) with ≤ 6 injections (early 
switch) and group 2 (n = 10) with > 6 injections (late switch). Table 1 shows the baseline demographics and 
ocular characteristics of the patients. At baseline, there were no significant differences in the mean age, mean 
duration of DME, and lens status (all P > 0.05) between the two groups. The mean follow-up duration was 
similar for groups 1 and 2 (P > 0.05). The number of previous intravitreal injections was significantly (P = 0.001) 
lower in group 1 (4.88 ± 1.36) than in group 2 (8.90 ± 2.03) and reflected fewer (P = 0.001) intravitreal anti-
VEGF injections in group 1 than in group 2 (3.88 ± 1.33 versus 7.80 ± 1.81, respectively) (Table 1). 
Table 1. Baseline characteristics of the study patients
Parameters Group 1 (n = 8) Group 2 (n = 10) P-value
Age (y), Mean ± SD 68.38 ± 9.21 68.80 ± 6.74 0.914
Time since DME diagnosis (y), Mean ± SD 1.63 ± 0.51 2.5 ± 1.26 0.069
Lens status (pseudophakic/phakic ratio), % 50/50 40/60 1.000
Previous treatments
Laser/intravitreal injections, % 100/100 80/100 0.706/1.000
Number of intravitreal injections, Mean± SD 4.88 ± 1.36 8.90 ± 2.03 0.001
Number of anti-VEGF intravitreal injections, Mean ± SD 3.88 ± 1.33 7.80 ± 1.81 0.001
Number of short-acting steroid (triamcinolone or dexamethasone) 
intravitreal injections, Mean ± SD 1.00 ± 0.54 1.10 ± 0.57 0.693
Follow-up period (months), Mean ± SD 16.37 ± 7.09 15.00 ± 12.94 0.657
BCVA (ETDRS visual score), Mean ± SD 52.50 ± 23.32 54.70 ± 15.68 0.721
CMT (µm), Mean ± SD 524.12 ± 196.56 549.00 ± 104.29 0.790
Abbreviations: n, number; y, years; SD, standard deviation; %, percentage; DME, diabetic macular edema; VEGF, vascular endothelial growth 
factor; BCVA, best-corrected visual acuity; ETDRS, Early Treatment of Diabetic Retinopathy Study chart; CMT, central macular thickness. 
P–value < 0.05 is shown in bold. Note: Group 1, ≤ 6 prior intravitreal injections (early switch); Group 2, > 6 intravitreal injections (late switch).
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Concerning OCT biomarkers at baseline, there was a higher percentage of eyes with DRIL (90.0% versus 
25.0%, respectively) and EZ disruption (80.0% versus 12.5%, respectively;) in group 2 than in group 1 (P < 0.05 
for both). The percentage of eyes with a combination of DRIL and EZ disruption was also significantly (P < 0.05) 
higher in group 2 (80.0 %) than in group 1 (12.5 %) (Figure 1). 
At the last observation point, there was a statistically significant reduction in the percentage of eyes with 
both DRIL and EZ disruption in group 2 than in the baseline (12.5% versus 80.0%, respectively; P < 0.05). The 
percentage of eyes with both DRIL and EZ disruption at the last observation in group 1 was the same as that 
observed at baseline (12.5% versus 12.5%, respectively).
Concerning functional outcomes, BCVA at baseline was similar (P > 0.05) in both groups (Table 1). After 
intravitreal injection of an FAc implant, a similar (all P > 0.05) percentage of eyes achieved vision stabilization or 
improvement at the last observation, gained ≥ 10 and ≥ 15 ETDRS letters from baseline, and achieved a visual 
acuity of ≥ 70 ETDRS letters (Figure 2). 
Figure 1. Presence of disorganization of the retinal inner layers (DRIL) and/or ellipsoid zone (EZ) disruption at baseline in Groups 1 and 2. 
Note: Group 1, ≤6  prior intravitreal injections (early switch); Group 2, > 6 intravitreal injections (late switch).
Figure 2. Visual acuity outcomes at the last observation in Groups 1 and 2. Abbreviations: ETDRS, Early Treatment Diabetic Retinopathy 
Study. Note: Group 1, ≤ 6 prior intravitreal injections (early switch); Group 2, > 6 intravitreal injections (late switch). 
Table 2. Intraocular pressure events at last observation in Groups 1 and 2
IOP events Group 1 Group 2 P-value
IOP ≥ 21 mmHg, n (%) 1 (12.5) 3 (30.0) 0.588
IOP-lowering medication at baseline, n (%) 3 (37.5) 0 (0.0) 0.069
Emer gent IOP-lowering medication at the last observation, n (%) 3 (37.5) 4 (40.0) 0.188
Trabeculoplasty, n (%) 0 (0.0) 0 (0.0) -
IOP-lowering surgery, n (%) 0 (0.0) 0 (0.0) -
Abbreviations: IOP, intraocular pressure; n, number; %, percentage. Note: Group 1, ≤ 6 prior intravitreal injections (early switch); Group 2, > 
6 intravitreal injections (late switch).
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At the last observation point, the mean BCVA gain was also clinically significant, with group 1 gaining +8.8 
letters versus group 2 gaining +0.7 letters. Although clinically significant, no statistically significant differences 
were detected between the groups (P = 0.397).
Concerning anatomical outcomes, the mean CMT was also similar in groups 1 and 2 at baseline (Table 1). 
Following treatment with an FAc implant, both groups showed sustained and continuous edema resolution (i.e., 
> 20% reduction from baseline) over the follow-up period with similar (P > 0.05) mean ± SD CMT values at the 
last observation in groups 1 and 2 (376.88 µm ± 104.93 versus 371.40 µm ± 183.23, respectively). There were no 
statistically or clinically significant differences between the two groups (P = 0.749). 
Concerning safety-related events, there was no significant (P = 0.242) change in mean IOP at the last 
observation in either group (Figure 3). IOP outcomes were also consistent between groups, with a similar 
percentage of eyes in both groups, achieving an IOP ≥ 21 mmHg and requiring IOP-lowering drops to control 
pressure. Interestingly, at baseline, none of the eyes in group 2 had been treated with IOP-lowering medication 
versus 37.5% of the eyes in group 1. Neither group required trabeculoplasty or IOP-lowering surgery (including 
trabeculectomy or any drainage devices) to manage high IOP (Table 2).
Figure 3. Mean Intraocular pressure (IOP) in millimeters of mercury (mmHg) at baseline and last observation in Groups 1 and 2.  P-value = 
0.242 between groups at the last observation.
Figure 4. Two spectral-domain optical coherence tomography horizontal scans of one patient from Group 1 at baseline (A), showing 
disorganization of the retinal inner layers (DRIL) and ellipsoid zone (EZ) disruption in the central foveal area and at last observation (B), 
showing resolution of DRIL and EZ disruption. 
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Figure 5. Two spectral-domain optical coherence tomography horizontal scans of one patient from Group 2 at baseline (A), showing 
disorganization of the retinal inner layers (DRIL) and ellipsoid zone (EZ) disruption in the central foveal area and at last observation (B), 
showing resolution of DRIL and EZ disruption. 
DISCUSSION
Our study revealed that group 1 (early switch group), which had a significantly lower percentage of eyes with 
DRIL and EZ disruption (alone or in combination) at baseline, achieved clinically higher main visual gain 
at the last observation than group 2 (+8.8 letters versus +0.7 letters, respectively; P > 0.05). The study also 
showed a statistically significant difference in the evolution of OCT biomarkers between the two groups, with 
resolution of these biomarkers at the last observation in most eyes from group 2. There were no statistically 
significant differences in anatomical and safety outcomes between the two groups.
OCT technology has facilitated the identification of DRIL and EZ disruption in patients with DME, 
thus shedding light on the prognosis of these patients. DRIL is a noninvasive parameter that seems to be 
a reliable predictor of visual outcomes in eyes with DME [17, 18]. A plausible explanation for this fact is 
that DRIL may reflect disorganization or compromised function of some anatomical structures considered 
critical for the transmission of visual information, such as bipolar, Müller, and horizontal cells [14, 15, 21]. 
In fact, the communication pathway between photoreceptors and ganglion cells mostly depends on bipolar 
cell integrity [22, 23]. When retinal thickness increases at a point capable of breaking its elastic limit caused 
by edema, bipolar axons may become damaged, which affects visual data signaling, ultimately leading to poor 
visual outcomes [18, 23]. This is especially true for the involvement of the immediate parafoveal area and 
could explain the robust association between DRIL and visual acuity described in the literature [6, 14, 18] 
and observed in our study. The presence of DRIL has been further considered a signal of macular capillary 
nonperfusion, which may also contribute to worse functional outcomes [20, 23]. 
The idea that chronicity plays an important role in DRIL development [18] is also reflected in our results, 
since group 2, which has a longer DME duration and performed a later switch to the FAc implant, had a higher 
percentage of eyes with DRIL (90.0% versus 25%.0%), EZ disruption (80.0% versus 12.5%), and both DRIL 
and EZ disruption (80.0% versus 12.5%) than group 1.
The literature suggests that the EZ layer reflects photoreceptor integrity and can also be considered an 
important predictor of visual prognosis in various retinal diseases [21, 24-28]. Similar to DRIL, several studies 
have suggested that EZ integrity is related to better visual outcomes after anti-VEGF and dexamethasone 
implant treatment [6, 14, 21]. Our study showed the same benefits after treatment with an FAc implant. It has 
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been suggested that DRIL is strongly related to disruption of the EZ layer and external limiting membrane 
integrity [15]. Our work confirms this relationship, since the majority of eyes with DRIL had EZ disruption. 
Maheshwary et al. concluded that the disruption of the photoreceptor inner and outer segments, as well as 
the percentage of this disruption, are both essential visual prognosticators in patients with DME [16]. It 
is possible that the mechanisms responsible for inner retinal layer disorganization may also play a role in 
concomitant disruption of the outer retinal anatomy [15]. 
In the present study, patients from group 1 achieved better functional outcomes. Although clinically 
significant, no statistically significant differences were detected between the groups (+8.8 letters versus 
+0.7 letters). These results can be explained by three reasons. First, since those eyes switched earlier to FAc 
implant treatment, they had shorter DME duration and consequently shorter exposure to the swelling effect 
on retinal anatomy integrity [28]. Second, those eyes had a lower percentage of DRIL and/or EZ disruption at 
baseline [14, 15]. Third, those eyes were also less exposed to the effect of consecutive, recurrent short-acting 
intravitreal treatments [2, 7]. The number of previous intravitreal injections was statistically different between 
the two groups, reflecting a possible association between these biomarkers and intravitreal injection number, 
supporting this hypothesis.
However, a small percentage of eyes achieving vision stability was also observed in group 2. The fact that 
DRIL may gradually regress after DME resolution, as observed in our patients (Figures 4 and 5), could explain 
these results [18, 21]. Indeed, there was a statistically significant difference in the evolution of prognostic 
biomarkers between the two groups, supporting the idea that FAc implants may improve retinal integrity. This 
finding also suggests that even eyes with a higher percentage of DRIL and EZ disruption may benefit, from an 
anatomical and visual viewpoint, from switching to FAc implants. 
The functional effectiveness outcomes obtained here are in agreement with the results of current reports 
and other studies of FAc implants for the treatment of recurrent and/or persistent DME in a real-world setting 
[7, 8]. In this regard, according to the ILUVIEN Registry Safety Study (IRISS), patients with short-term 
and long-term DME gained approximately nine letters and one letter, respectively, at month 15, which is 
consistent with our findings [19]. All these results support the idea that switching to an FAc implant as soon 
as an insufficient response to previous treatment is detected could have more functional advantages. 
In our study, the early or late switch to the FAc implant did not have an impact on the anatomical results. 
Structurally, the mean reduction in CMT was similar in both groups, which showed sustained and continuous 
edema resolution, in both cases exceeding 20% reduction from the baseline value. In relation to safety 
outcomes, there was no significant change in mean IOP at the last observation in either group. IOP outcomes 
were also consistent in the two groups, with a similar percentage of eyes achieving an IOP ≥ 21 mmHg and 
requiring IOP-lowering drops to control pressure. 
The major limitations of this study are its retrospective nature and the limited number of treated eyes. 
However, to reduce or eliminate some of the data acquisition inconsistencies, the present study included 
methodological approaches, such as extended electronic medical data reports, certified ETDRS visual acuity 
measures, and SD-OCT image acquisition following the protocol, thus maximizing the accuracy of clinical 
data. Although prospective and randomized studies, including a larger patient cohort, are warranted to obtain 
further conclusions. The analysis of morphological features and biomarkers on SD-OCT scans is expected to 
have a growing importance in managing treatment and visual outcome expectations in patients with DME.
CONCLUSIONS
This study showed the benefit of switching to an FAc implant in patients with chronic DME after an insufficient 
response to other intravitreal treatments, especially if done early. OCT biomarkers, namely DRIL and/or EZ 
disruption, are useful prognostic predictors, particularly in DME management.
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